Fate Therapeutics

Fate Therapeutics (NASDAQ: FATE) is a clinical-stage biopharmaceutical company dedicated to developing first-in-class cellular immunotherapies for cancer patients. We believe that better cell therapies start with better cells. To produce superior cell therapies, we utilize human induced pluripotent stem cells (iPSCs) generated from our proprietary iPSC product platform to create genetically engineered clonal master iPSC lines with preferred biological properties. We can direct and determine the fate of our clonal master iPSC lines to produce well-defined and uniformly composed NK and T cell products.